Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Tarsus Pharmaceuticals, Inc. - Common Stock (NQ:TARS)

69.81 +0.85 (+1.23%)
Streaming Delayed Price Updated: 11:07 AM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Tarsus Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Tarsus to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Capricorn Fund Loads Up on Phreesia (PHR) With a 484,000 Share Purchase
Capricorn Fund Loads Up on Phreesia (PHR) With a 484,000 Share Purchase 
Via The Motley Fool
Capricorn Buys New Stake in Ionis Pharmaceuticals (IONS) With 163,000 Shares
Via The Motley Fool
Tarsus to Participate in Upcoming Investor Conferences
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Earnings Scheduled For August 6, 2025
 
Via Benzinga
Earnings Scheduled For May 1, 2025
 
Via Benzinga
An Overview of Tarsus Pharmaceuticals's Earnings
 
Via Benzinga
Earnings Scheduled For February 25, 2025
 
Via Benzinga
3 Biotech Catalysts Present Major Opportunity
Three promising biotech names stand out for potentially catalyzing drugs currently on the market or in development; here's why they may rally further. 
Via MarketBeat
Top 2 Health Care Stocks That May Fall Off A Cliff In August
 
Via Benzinga
Tarsus Reports Second Quarter 2025 Financial Results and Recent Business Achievements
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tarsus to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
A Glimpse Into The Expert Outlook On Tarsus Pharmaceuticals Through 4 Analysts
 
Via Benzinga
Tarsus to Participate in Upcoming Investor Conferences
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tarsus Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
 
Via Benzinga
Tarsus to Participate in Upcoming Investor Conferences
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
6 Analysts Assess Tarsus Pharmaceuticals: What You Need To Know
 
Via Benzinga
Elanco Animal Health Sells Xdemvy Royalties To Blackstone in $295 Million Deal
Elanco sells U.S. Xdemvy royalties to Blackstone for $295 million, aiming to lower debt and cut interest costs while retaining global rights. 
Via Benzinga
Tarsus Reports First Quarter 2025 Financial Results and Recent Business Achievements
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tarsus to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Would Mark Minervini consider TARSUS PHARMACEUTICALS INC (NASDAQ:TARS) a top stock pick?
Exploring high growth characteristics of TARSUS PHARMACEUTICALS INC (NASDAQ:TARS). A fundamental and technical analysis of (NASDAQ:TARS). 
Via Chartmill
Tarsus to Present Several Scientific Abstracts Highlighting the Global Prevalence of Demodex Blepharitis and the Clinical Impact of XDEMVY at the American Society of Cataract and Refractive Surgery (ASCRS) 2025 Annual Meeting
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Why Mark Minervini may look into TARSUS PHARMACEUTICALS INC (NASDAQ:TARS)
A fundamental and technical analysis of (NASDAQ:TARS): Why the high growth investor may take a look at TARSUS PHARMACEUTICALS INC (NASDAQ:TARS). 
Via Chartmill
Tarsus Announces Pricing of Upsized $125.0 Million Public Offering
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tarsus Announces Proposed $100.0 Million Public Offering
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tarsus to Participate in Upcoming Investor Conference
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tarsus to Report Fourth Quarter and Full-Year 2024 Financial Results on Tuesday, February 25, 2025
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tarsus to Participate in Upcoming Investor Conferences
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tarsus Provides 2025 Update: Accelerating the Launch of XDEMVY® and Establishing Ocular Rosacea as the Next Category-Creating Opportunity in Eye Care
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
How Tarsus Pharmaceuticals' Unique Inspiration Is Driving A Triple-Digit Run
The company sells one drug to treat a condition that causes dry, red and itchy eyes. But rosacea and Lyme disease could be next. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.